文献速递脑血管病

Adropin对老年小鼠短暂性缺血性卒中后血脑屏障损伤的治疗益处

Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage.
PubMed 文献 · Stroke · 2022-10-28

该研究在18-24月龄雄性小鼠短暂性大脑中动脉闭塞模型中发现,再灌注时给予合成Adropin肽可减小梗死体积和脑水肿、改善运动功能,延迟4小时给药可减轻体重下降并改善长期认知功能,其机制与减少MMP-9和保留紧密连接蛋白有关。

要点

  • 再灌注时给予合成Adropin肽可显著减小老年小鼠梗死体积和脑水肿。
  • 卒中后4小时延迟给予Adropin可减轻体重下降、减小梗死体积并改善长期认知功能。
  • Adropin的保护作用与减少MMP-9和保留紧密连接蛋白相关。

核心结论

  • Adropin在老年脑短暂性缺血性卒中后通过减少神经血管损伤发挥有前景的神经保护作用。
  • 作者认为卒中后Adropin治疗是减轻缺血性卒中患者脑损伤和促进功能恢复的潜在策略。

研究设计与样本

  • 研究使用18-24月龄雄性小鼠,接受30分钟大脑中动脉闭塞后48小时或14天再灌注。
  • 在预定时间点进行感觉运动测试(握力试验和旷场)和认知测试(Y迷宫和新物体识别)。
  • 梗死体积通过48小时2,3,5-三苯基四氮唑氯化物染色或14天甲酚紫染色定量。
  • 血脑屏障损伤、紧密连接蛋白和MMP-9在48小时后通过ELISA和Western blot评估。

主要发现

  • Enho基因缺失显著增加梗死体积并加重神经功能,而Adropin过表达相比野生型对照大幅减小卒中体积。
  • 再灌注开始时给予合成Adropin肽显著减小48小时梗死体积和脑水肿,并改善运动功能和肌力。
  • 卒中发作后4小时延迟Adropin治疗减轻体重下降、减小梗死体积和肌力功能障碍,并改善长期认知功能。
  • 缺血后Adropin治疗显著减少血脑屏障损伤,与减少MMP-9和保留紧密连接蛋白相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adropin is a peptide encoded by the energy homeostasis-associated gene (Enho) that is highly expressed in the brain. Aging and stroke are associated with reduced adropin levels in the brain and plasma. We showed that treatment with synthetic adropin provides long-lasting neuroprotection in permanent ischemic stroke. However, it is unknown whether the protective effects of adropin are observed in aged animals following cerebral ischemia/reperfusion. We hypothesized that adropin provides neuroprotection in aged mice subjected to transient middle cerebral artery occlusion. METHODS: Aged (18-24 months old) male mice were subjected to 30 minutes of middle cerebral artery occlusion followed by 48 hours or 14 days of reperfusion. Sensorimotor (weight grip test and open field) and cognitive tests (Y-maze and novel object recognition) were performed at defined time points. Infarct volume was quantified by 2,3,5-triphenyltetrazolium chloride staining at 48 hours or Cresyl violet staining at 14 days post-middle cerebral artery occlusion. Blood-brain barrier damage, tight junction proteins, and MMP-9 (matrix metalloproteinase-9) were assessed 48 hours after middle cerebral artery occlusion by ELISA and Western blots. RESULTS: Genetic deletion of Enho significantly increased infarct volume and worsened neurological function, whereas overexpression of adropin dramatically reduced stroke volume compared to wild-type controls. Postischemic treatment with synthetic adropin peptide given at the onset of reperfusion markedly reduced infarct volume, brain edema, and significantly improved locomotor function and muscular strength at 48 hours. Delayed adropin treatment (4 hours after the stroke onset) reduced body weight loss, infarct volume, and muscular strength dysfunction, and improved long-term cognitive function. Postischemic adropin treatment significantly reduced blood-brain barrier damage. This effect was associated with reduced MMP-9 and preservation of tight junction proteins by adropin treatment. CONCLUSIONS: These data unveil a promising neuroprotective role of adropin in the aged brain after transient ischemic stroke via reducing neurovascular damage. These findings suggest that poststroke adropin therapy is a potential strategy to minimize brain injury and improve functional recovery in ischemic stroke patients.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yang C, Liu L, Lavayen BP, et al. Therapeutic Benefits of Adropin in Aged Mice After Transient Ischemic Stroke via Reduction of Blood-Brain Barrier Damage. Stroke. 2022. PMID: 36305313. doi:10.1161/STROKEAHA.122.039628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。